BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Sarepta Therapeutics (SRPT)Sarepta TherapeuticsCompany update

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 26, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov.

Related news

SRPTSarepta Therapeutics2026-09-24 12:30 EST

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

SRPTSarepta Therapeutics2026-08-31 20:30 EST

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

ABEOAbeona Therapeutics2026-09-02 11:30 EST

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

VYGRVoyager Therapeutics2026-09-01 12:00 EST

Voyager to Present at Upcoming Investor Conferences

NTLAIntellia2026-10-29 12:00 EST

Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026

OCGNOcugen2026-10-29 11:02 EST

Ocugen to Participate in Upcoming November Investor and Industry Conferences

MXCTMaxCyte2026-10-28 12:06 EST

MaxCyte to Participate in Three Upcoming Investor Conferences

OCGNOcugen2026-09-29 11:02 EST

Ocugen to Participate in Upcoming October Investor and Industry Conferences

RCKTRocket Pharmaceuticals2026-09-03 11:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

SANASana Biotechnology2026-09-01 20:05 EST

Sana Biotechnology to Present at September 2026 Investor Conferences

View all latest news

Sarepta Therapeutics

Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy. ELEVIDYS ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients...

Recent company news

SRPTSarepta Therapeutics2026-11-05 21:05 EST

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-10-26 20:30 EST

Sarepta Therapeutics to Present at Upcoming Investor Conferences

SRPTSarepta Therapeutics2026-10-22 12:30 EST

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

SRPTSarepta Therapeutics2026-10-14 12:30 EST

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

SRPTSarepta Therapeutics2026-09-30 20:30 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
17.57 USD
Market cap
1.72B USD
Exchange
NASDAQ
Sector
Gene Therapy
Location
United States